Bicycle Therapeutics to Present Updated Data from Phase I/IIa Trial Evaluating Lead Asset BT1718 in Patients with Advanced Solid Tumors at ESMO 2019 Annual Congress

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Sep. 24, 2019-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) product platform, today announced that updated data from the Phase I dose escalation portion of the Phase I/IIa trial evaluating the Company’s lead asset BT1718 in patients with advanced solid tumors will be presented at the European Society of Medical Oncology (ESMO) 2019 Annual Congress, September 27 – October 1 in Barcelona, Spain. Details for the poster presentation are as follows: Session Title: Poster Session 2 Location: Poster Area (Hall 4) Poster Presentation Title: Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumors Abstract #: 5764 Date & Time: September 28, 2019, 12:00 p.m. – 1:00 p.m. CET About Bicycle Therapeutics Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20190924005192/en/ Source: Bicycle Therapeutics Investors: Bicycle Therapeutics Maren Killackey [email protected] +1-617-203-8300 Media: Ten Bridge Communications Sara Green [email protected] +1-617-233-1714 Press Releases Close IR Nav Overview →Stock Information →SEC Filings →Annual General Meeting →UK Annual Reports →Governance + Leadership →Presentation + Events →Analyst Coverage →Press Releases →Investor Resources → IR Nav Overview Stock Information SEC Filings Annual General Meeting UK Annual Reports Governance + Leadership Presentation + Events Analyst Coverage Press Releases Investor Resources United Kingdom Blocks A & B Portway Building Granta Park Great Abington Cambridge CB21 6GP View Google Map United States 4 Hartwell Place Lexington, MA 02421 View Google Map General Enquiries [email protected] Follow LinkedIn Twitter Privacy © Bicycle Therapeutics 2026 Designed by Greenspace Sign up Search Close Search Search → Hello We use cookies and other technologies to optimise your experience and analyse our traffic. Please confirm you are happy to accept. You can change your preferences in Cookie Settings. Find out more Accept var s_CCSWebHostingAccount = "trcgbicycle"; {"path":{"baseUrl":"\/","pathPrefix":"","currentPath":"node\/6831","currentPathIsAdmin":false,"isFront":false,"currentLanguage":"en","themeUrl":"sites\/g\/files\/knoqqb78741\/themes\/site\/nir_pid3307"},"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJyNkdFuQyEIhl-oOTbpxR6HoLLWHYUToNv69rW6pO2yZYsXCn7y8yMXBWSsFy_JAj9GC2aJBBXPnE47_hPcVPLAIhoNoiRhe065SI2oI5lWysVFIaP3FStZuB-XVxV24lmzoa7kg4RYJa1hyJuDohc-doVe8ITq_8INhsgvbCNkUErSWtfvD4Qfa5-rl9Zbx_AcjtsNj9Pp7bDgG34C5gypohlgJXX7gUvDqoNdOHUrzDRHtJV8OOxfgryTasmz4Q-KVpyApU-f5md8yy1f-866Z2rhNv8rJ2XCOg","theme":"nir_pid3307","theme_token":null},"ajaxTrustedUrl":[],"nir_admin_use_chosen":true,"nir_admin_use_select2":false,"user":{"uid":0,"permissionsHash":"364a63fdd1ba8bf28808b7d4a735dfbd500f3bdd6295cc883846cac82cce7d97"}}

The release as fetched from its publisher. bicycletherapeutics.com ↗